1. Home
  2. GSIW vs COCP Comparison

GSIW vs COCP Comparison

Compare GSIW & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

HOLD

Current Price

$15.41

Market Cap

24.2M

Sector

N/A

ML Signal

HOLD

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$1.22

Market Cap

21.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIW
COCP
Founded
2016
2006
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
21.6M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
GSIW
COCP
Price
$15.41
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
51.6K
50.3K
Earning Date
08-04-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.65
EPS
N/A
N/A
Revenue
N/A
$12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.76
52 Week High
$38.55
$2.03

Technical Indicators

Market Signals
Indicator
GSIW
COCP
Relative Strength Index (RSI) N/A 56.49
Support Level N/A $1.17
Resistance Level N/A $1.25
Average True Range (ATR) 0.00 0.07
MACD 0.00 -0.00
Stochastic Oscillator 0.00 47.37

Price Performance

Historical Comparison
GSIW
COCP

About GSIW Garden Stage Limited

Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: